Department of Urology, Case Medical Center/University Hospitals of Cleveland, Cleveland, OH 44106, USA.

This email address is being protected from spam bots, you need Javascript enabled to view it

An efficacy study of tadalafil (5 mg once daily) for treating erectile dysfunction included sexual satisfaction and psychosocial outcome measures such as Treatment satisfaction (THX) domain of Sexual Life Quality Questionnaire, Self-Esteem And Relationship (SEAR) questionnaire, Sexual Encounter Profile questions 4 (SEP4; hardness satisfaction) and 5 (SEP5; overall satisfaction), intercourse satisfaction (IS) and overall satisfaction (OS) domains of International Index of Erectile Function (IIEF), and partner SEP question 3 (pSEP3). After a 4-week run-in phase, participants were randomized to receive either tadalafil (N=264) or placebo (N=78) for 12 weeks. Participants and partners were more satisfied (THX) with tadalafil (75 and 73, respectively) than with placebo (51 and 55, respectively, P< 0.001). Statistically significant improvements in sexual relationship, confidence, self-esteem and overall relationship (SEAR), in addition to IS, OS, SEP5 and pSEP3 for tadalafil compared with placebo (P< 0.001) correlated with erectile function (EF) improvement (assessed by change from baseline in IIEF-EF score). Tadalafil significantly improved treatment and sexual satisfaction, while improving multiple outcomes measured by SEAR.

Written by:
Seftel AD, Buvat J, Althof SE, McMurray JG, Zeigler HL, Burns PR, Wong DG.   Are you the author?

Reference:
Int J Impot Res. 2009 Jul-Aug;21(4):240-8.
doi:10.1038/ijir.2009.22

PubMed Abstract
PMID:19536128

UroToday.com Erectile Dysfunction (ED) Section

Please log-in or register in order to submit comments.

Powered by AkoComment!